Vanta Bioscience

Vanta Bioscience EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Vanta Bioscience (540729.BO) as of Oct 29, 2026 is -9.23. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -104.01 — a change of -91.12% (higher).

EV/FCF

-9.23

YoY

-91.12%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Vanta Bioscience is 2025 -9.23 . EV/FCF (Enterprise Value to Free Cash Flow) of Vanta Bioscience was 2024 -104.01 . It decreases by -91.12% higher compared to the previous year.

The Vanta Bioscience EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-5.90 INR
Jan 1, 2020
-5.97 INR
Jan 1, 2021
-3.10 INR
Jan 1, 2022
-4.92 INR
Jan 1, 2023
-2.43 INR
Jan 1, 2024
-104.01 INR
Jan 1, 2025
-9.23 INR
The Vanta Bioscience EV/FCF history
YEAREV/FCFYoY
-9.23-91.12%
-104.01+4,180.63%
-2.43-50.59%
-4.92+58.71%
-3.10-48.14%
-5.97+1.21%
-5.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vanta Bioscience Stock analysis

What does Vanta Bioscience do? Vanta Bioscience Ltd. generates revenue by offering comprehensive preclinical contract research services to pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. The company provides preclinical safety assessment services, risk assessment for active pharmaceutical ingredients (API), excipients, extractable and leachable substances, and pharmaceutical impurities. It also delivers health-based exposure limit determinations including permitted daily exposure (PDE), allowable daily exposure (ADE), and occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's clients across diverse sectors rely on its analytical testing, environmental studies, and research services for regulatory compliance and product safety validation. Vanta Bioscience Ltd. operates as a full-service preclinical contract research organization with a focus on delivering specialized safety assessments and exposure limit evaluations to support client product development and market entry. Its service portfolio includes clinical research, pre-clinical research, biopharma services, analytical testing, and environmental studies, catering to industries requiring rigorous safety evaluations before product launch. The company's expertise in risk assessment for pharmaceutical ingredients and related substances enables it to serve a broad range of clients in the biopharma and chemical sectors. Vanta Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vanta Bioscience stock

EV/FCF (Enterprise Value to Free Cash Flow) of Vanta Bioscience is -9.23 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Vanta Bioscience changed from -104.01 to -9.23, representing a -91.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Vanta Bioscience since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Vanta Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Vanta Bioscience

All Key Metrics — Vanta Bioscience